文献速递乳腺癌

靶向治疗时代原发性转移性乳腺癌:预后影响与乳腺肿瘤手术的作用

Primary metastatic breast cancer in the era of targeted therapy - Prognostic impact and the role of breast tumour surgery.
PubMed 文献 · Eur J Cancer · 2017-07-20

手术组无进展生存期和总生存期数值上略优但未达统计学显著,多变量分析中手术与PFS(HR 0.99;P=0.92)和OS(0.95;P=0.71)均无显著关联。作者认为在现代靶向治疗下局部切除对总体PMBC人群无明显生存获益,但需进一步分析以界定可能获益的特定风险组。

要点

  • 570例(24%)为原发性转移性乳腺癌,568例有原发灶切除信息,426例(75%)接受局部切除。
  • 手术组PFS中位13.6个月 vs 非手术组11.8个月(P=0.18),OS中位34.1个月 vs 31.7个月(P=0.23),均未达统计学显著。
  • 多变量分析中手术与PFS(HR 0.99;P=0.92)和OS(HR 0.95;P=0.71)均无显著关联。

核心结论

  • 作者认为在现代靶向治疗下局部切除对总体原发性转移性乳腺癌人群无明显生存获益。
  • 作者指出需进一步分析以界定可能从原发灶手术切除中获益的特定风险组。

研究设计与样本

  • 一项研究探讨曲妥珠单抗联合主要以一线化疗为主的方案治疗HER2阳性转移性乳腺癌。
  • 另一项研究观察贝伐珠单抗联合化疗作为主要为HER2阴性疾病的一线治疗。
  • 570例(24%)为原发性转移性乳腺癌,568例有原发灶切除的有效信息,426例(75%)接受了局部切除。

主要发现

  • 手术组总体转移负荷较少且T4肿瘤比例较低,两组在年龄、激素受体和HER2状态、内脏疾病和体力状态方面无主要差异。
  • 手术组PFS中位13.6个月 vs 非手术组11.8个月(P=0.18),未达统计学显著。
  • 手术组OS中位34.1个月 vs 非手术组31.7个月(P=0.23),未达统计学显著。
  • 多变量分析纳入所有其他单变量显著参数后,手术与PFS(HR 0.99;P=0.92)和OS(HR 0.95;P=0.71)均无显著关联。

临床怎么用

  • 作者认为在现代靶向治疗下局部切除对总体原发性转移性乳腺癌人群无明显生存获益。
  • 作者指出需进一步分析以界定可能从原发灶手术切除中获益的特定风险组。

局限性

  • 作者指出需进一步分析以界定可能从原发灶手术切除中获益的特定风险组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Except for meeting the individual palliative need, the benefit of breast surgery in primary metastatic breast cancer (PMBC), also known as de novo metastatic breast cancer, on long-term outcomes remains controversial. Twenty-four hundred and one patients with metastatic breast cancer, enrolled between 2000 and 2011 in two prospective non-interventional studies on targeted therapy, were screened with respect to this question. METHODS: One study investigated trastuzumab therapy for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer in addition to mainly first-line chemotherapy. The other observed bevacizumab added to chemotherapy as first-line treatment for mostly HER2-negative disease. RESULTS: Five-hundred and seventy (24%) patients presented with PMBC, and valid information on resection of the primary tumour was available for 568 women. Out of these, 426 (75%) underwent local resection. The latter group was characterised by less overall metastatic burden and a lower proportion of T4 tumours. No major differences were observed with respect to age, hormone receptor and HER2 status, visceral disease and performance status. Numerically, the surgery group showed a slightly favourable progression-free survival (PFS, medians: 13.6 versus 11.8 months; P = 0.18) and overall survival (OS, 34.1 versus 31.7; P = 0.23). However, in multivariable analysis, including all other univariably significant parameters, no trend for better outcome after surgery remained detectable, neither for PFS (hazard ratio 0.99; P = 0.92) nor for OS (0.95; P = 0.71). CONCLUSIONS: Our findings suggest no major survival benefit for local resection in the overall PMBC population treated with modern targeted therapies. However, further analyses are warranted to define specific risk groups, which may benefit from surgical removal of the primary.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Barinoff J, Schmidt M, Schneeweiss A, et al. Primary metastatic breast cancer in the era of targeted therapy - Prognostic impact and the role of breast tumour surgery. Eur J Cancer. 2017. PMID: 28735068. doi:10.1016/j.ejca.2017.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。